A Phase 4 interventional study of Ocrelizumab 300 mg and Ocrelizumab 600 mg in Multiple Sclerosis, sponsored by Hoffmann-La Roche. Completed at 46 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-11.
Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing ocrelizumab in Multiple Sclerosis — 3 open to participants now, 14 under way, 8 of them phase 3. ocrelizumab · Multiple Sclerosis.
Among the 27 studies testing ocrelizumab in Multiple Sclerosis, this one is the 8th largest by enrollment, is one of 3 that started in 2018, is one of 11 in phase 4, and was the 5th registered.
3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →3 of the 27 studies testing ocrelizumab in Multiple Sclerosis are open now, in 8 countries. Recruiting first, the newest first:
Genentech, Inc. · Sites in United States, Puerto Rico
Ages 18–65
Hoffmann-La Roche · Sites in Bulgaria, France, Germany and 3 more countries
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–60 · Healthy volunteers
By country, each count listing its studies:
ocrelizumab: first FDA approval 2017 (OCREVUS), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 3 started in 2018.
This study's enrollment of 423 is above the median of 50 across 2,207 interventional studies indexed under Multiple Sclerosis.
Median enrollment 170 across the 27 interventional studies. Of the 12 that completed or were terminated, 8 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 27 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
35 studies in Multiple Sclerosis by Hoffmann-La Roche: 6 open now, 17 under way, 7 of them phase 3. Of 14 finished, 7 (50%) have results posted.
Among the 35 studies in Multiple Sclerosis by Hoffmann-La Roche, this one is the 12th largest by enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2018, is one of 6 in phase 4, and was the 10th registered.
Hoffmann-La Roche’s Multiple Sclerosis studies by the year they started, since 2004.
1 of the studies testing ocrelizumab in Multiple Sclerosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04466150University of California, San FranciscoImpact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 27 studies testing ocrelizumab in Multiple Sclerosis, from their registry updates:
Among Hoffmann-La Roche’s 35 in Multiple Sclerosis:
This tab as a report to print or save as PDF → With an account.
This national, open-label study is designed to give complementary efficacy, safety and patient reported outcomes (PROs) data in participants with active relapsing forms of MS. Participants will receive a maximum of 2 treatment cycles of ocrelizumab infusions: an initial dose of two 300 milligram (mg) infusions separated by 14 days followed by one single infusion of 600 mg ocrelizumab 24 weeks after the first infusion. Disease activity is determined by clinical relapses and/or Magnetic Resonance Imaging (MRI) activity.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Each participant will receive an initial dose of two 300 mg infusions of Ocrelizumab each separated by 14 days followed by one single dose of 600 mg 24 weeks after the initial dose.
Drug: Ocrelizumab 300 mg · Drug: Ocrelizumab 600 mg
Two doses of 300 mg infusion administered 14 days apart.
A single does of 600 mg infusion administered 24 weeks after the initial dose.
Percentage of participants free of disease activity
This outcome measure evaluates the impact of ocrelizumab on disease activity in participants with active Relapsing Multiple Sclerosis (RMS). Freedom of disease activity is defined as participant without any relapse from enrollment to Week 48 and without T1 Gadolinium-enhancing lesion detected by brain MRI at Week 48 and without any new and/or enlarging T2 lesion detected by brain MRI at Week 48.
Time frame: From Enrollment to Week 48
Annualized relapse rate
Annualized relapse rate is defined as the total number of clinical relapses divided by the number of participant-years of study treatment exposure. This outcome measure describes the efficacy of ocrelizumab in active RMS participants.
Time frame: At Week 48
Percentage of participants with stable, improved, or worsened expanded disability status scale (EDSS)
This outcome measure describes the efficacy of ocrelizumab in active RMS participants.
Time frame: From Enrollment to Week 48
Percentage of participants with confirmed disability progression at Week 24 (CDP24)
This outcome measure describes the efficacy of ocrelizumab in active RMS participants.
Time frame: At Week 48
Mean Change in EDSS
This outcome measure describes the efficacy of ocrelizumab in active RMS participants.
Time frame: From Baseline to Week 48
Percentage of relapse-free RMS participants
This outcome measure describes the efficacy of ocrelizumab in active RMS participants.
Time frame: From Enrollment to Week 24 and Week 48
Percentage of participants with no T1 gadolinium-enhancing lesion and no new and/or enlarging T2 lesion as detected by brain MRI
This outcome measure describes the efficacy of ocrelizumab in active RMS participants.
Time frame: At Week 48
Percentage of participants with no T1 gadolinium-enhancing lesion as detected by brain MRI
This outcome measure describes the efficacy of ocrelizumab in active RMS participants.
Time frame: At Week 48
Percentage of participants with no new and/or enlarging T2 lesion as detected by brain MRI
This outcome measure evaluates the impact of ocrelizumab on disease activity in participants with active RMS.
Time frame: At Week 48
Change in the score of MS symptom severity scale (SymptoMScreen)
This outcome measure describes the impact of ocrelizumab on patient reported outcomes (MS symptom severity, fatigue, health-related quality of life with standard and disease specific scales, work productivity, and treatment satisfaction) in active RMS patients.
Time frame: At Week 24 and Week 48
Change in the score of Modified Fatigue Impact Scale (MFIS)
This outcome measure describes the impact of ocrelizumab on patient reported outcomes (MS symptom severity, fatigue, health-related quality of life with standard and disease specific scales, work productivity, and treatment satisfaction) in active RMS patients.
Time frame: At Week 24 and Week 48
Change in the score of EuroQol 5-Dimension Questionnaire (EQ-5D-5L with Visual Analogue Scale (VAS)) for health-related quality of life
This outcome measure describes the impact of ocrelizumab on patient reported outcomes (MS symptom severity, fatigue, health-related quality of life with standard and disease specific scales, work productivity, and treatment satisfaction) in active RMS patients.
Time frame: At Week 24 and Week 48
Change in the score of Work Productivity and Activity Impairment scale (WPAI:SHP)
This outcome measure describes the impact of ocrelizumab on patient reported outcomes (MS symptom severity, fatigue, health-related quality of life with standard and disease specific scales, work productivity, and treatment satisfaction) in active RMS patients.
Time frame: At Week 24 and Week 48
Change in the score of Multiple Sclerosis International Quality Of Life Questionnaire (MusiQOL)
This outcome measure describes the impact of ocrelizumab on patient reported outcomes (MS symptom severity, fatigue, health-related quality of life with standard and disease specific scales, work productivity, and treatment satisfaction) in active RMS patients.
Time frame: At Week 24 and Week 48
Change in the score of Treatment Satisfaction Questionnaire for Medication (TSQM-14)
This outcome measure describes the impact of ocrelizumab on patient reported outcomes (MS symptom severity, fatigue, health-related quality of life with standard and disease specific scales, work productivity, and treatment satisfaction) in active RMS patients.
Time frame: At Week 24 and Week 48
Percentage of Participants with Adverse Events (AE)
This outcome measure describes ocrelizumab safety in active RMS patients. Severity of AEs is determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v4.0)
Time frame: From Baseline to Week 48
Ran from Aug 2018 to primary completion in Feb 2021, 30 months.
Of 36 industry-sponsored phase 4 interventional studies under Multiple Sclerosis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 37. This study's 30 months is close to that.
Counting every sponsor, half of 69 studies reached it within 34 months; a quarter within 23 and three quarters within 59.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ocrelizumab